BCAL Diagnostics Limited is a biotechnology company specializing in the development of advanced blood-based diagnostic technologies, with a particular focus on early detection and ongoing monitoring of breast cancer. The company’s key innovation is a non-invasive blood test known as BREASTEST, which utilizes cutting-edge Liquid Chromatography Mass Spectrometry (LCMS) to deliver reliable, accurate results. Designed to complement existing imaging methods such as mammograms, BCAL Diagnostics’ solutions aim to improve clinical outcomes by enabling safer, faster, and broader breast cancer screening for women of all ages, backgrounds, and geographic locations. Since its founding in 2010, the company has emphasized accessibility and cost-effectiveness in its approach, seeking to make high-quality diagnostics available to a global female population. Through continuous research, clinical trials, and the operation of a NATA-accredited laboratory, BCAL Diagnostics plays a significant role in the healthcare sector, advancing innovation in cancer diagnostics and supporting healthcare professionals with powerful tools to enable earlier intervention and improved patient care.